(Q37906356)

25 August 2017

1 reference

title

Update on the management of Crohn's disease (English)

1 reference

25 August 2017

0 references

Anna M Buchner

1

1 reference

25 August 2017

Wojciech Blonski

series ordinal

2

1 reference

25 August 2017

Gary R Lichtenstein

series ordinal

3

1 reference

25 August 2017

language of work or name

1 reference

1 October 2011

1 reference

Current gastroenterology reports

25 August 2017

published in

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

465-474

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Disease activity courses in a regional cohort of Crohn's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Management of Crohn's disease in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

The use of budesonide in the treatment of active Crohn's disease is good clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

The role of bacteria in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Thiopurine methyltransferase genotype distribution in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

The comeback kid: TYSABRI now FDA approved for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0220-X

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

21 January 2018

1 reference

12 December 2020

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

12 December 2020

Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease

1 reference

12 December 2020

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

12 December 2020

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

12 December 2020

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

12 December 2020

Methotrexate for induction of remission in refractory Crohn's disease

1 reference

12 December 2020

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

12 December 2020

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

12 December 2020

Infliximab Use and Hepatosplenic T Cell Lymphoma: Questions to Be Asked and Lessons Learned

1 reference

12 December 2020

Budesonide for maintenance of remission in Crohn's disease

1 reference

12 December 2020

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

1 reference

12 December 2020

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease

1 reference

12 December 2020

Natalizumab and progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Methotrexate for maintenance of remission in Crohn's disease

1 reference

12 December 2020

The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota

1 reference

12 December 2020

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis

1 reference

12 December 2020

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

1 reference

12 December 2020

Azathioprine for maintaining remission of Crohn's disease

1 reference

12 December 2020

Aminosalicylates for induction of remission or response in Crohn's disease

1 reference

12 December 2020

The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics

1 reference

12 December 2020

Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease

1 reference

12 December 2020

Anti-tuberculous therapy for maintaining remission of Crohn's disease

1 reference

12 December 2020

Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis

1 reference

12 December 2020

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

12 December 2020

National Cooperative Crohn's Disease Study: results of drug treatment

1 reference

12 December 2020

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

1 reference

12 December 2020

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

12 December 2020

European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment

1 reference

12 December 2020

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission

1 reference

12 December 2020

Natalizumab for induction of remission in Crohn's disease

1 reference

12 December 2020

Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin

1 reference

12 December 2020

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

12 December 2020

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

12 December 2020

6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come

1 reference

12 December 2020

Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience

1 reference

12 December 2020

Budesonide for induction of remission in Crohn's disease

1 reference

12 December 2020

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

1 reference

12 December 2020

10.1007/S11894-011-0220-X

Identifiers

DOI

1 reference

25 August 2017

1 reference